Sucampo Pharmaceuticals, Inc. to Present Results From Four Phase 3 Studies of AMITIZA® (lubiprostone) for Opioid-Induced Constipation at PAINWeek 2013

Published: Sep 05, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BETHESDA, Md., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") will be presenting data from four separate phase 3 studies evaluating the overall efficacy of AMITIZA (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC). One of the presentations will also include results of AMITIZA's long-term safety and another will highlight novel data indicating that the treatment does not interfere with the analgesic effect of opioids in adult patients. Sucampo will present these data during PAINWeek 2013 in Las Vegas on Thursday, September 5, at 6:15 p.m. PDT.

Help employers find you! Check out all the jobs and post your resume.

Back to news